AAAAAA

   
Results: << | 401-425 | 426-450 | 451-475 | 476-500 | >>

Table of contents of journal: The *Prostate

Results: 451-475/1162

Authors: Fattaey, HK Quinton, TM Zhao, K He, F Paulsen, AQ Johnson, TC
Citation: Hk. Fattaey et al., CeReS-18 inhibits growth and induces apoptosis in human prostatic cancer cells, PROSTATE, 38(4), 1999, pp. 285-295

Authors: Crawford, ED Leewansangtong, S Goktas, S Holthaus, K Baier, M
Citation: Ed. Crawford et al., Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff forabnormal values, PROSTATE, 38(4), 1999, pp. 296-302

Authors: Brothman, AR Maxwell, TM Cui, J Deubler, DA Zhu, XL
Citation: Ar. Brothman et al., Chromosomal clues to the development of prostate tumors, PROSTATE, 38(4), 1999, pp. 303-312

Authors: Koutsilieris, M Tzanela, M Dimopoulos, T
Citation: M. Koutsilieris et al., Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: Case report, PROSTATE, 38(4), 1999, pp. 313-316

Citation: Abstracts from the 1998 International Symposium on Biology of Prostate Growth - National Institutes of Health - Natcher Conference Center - Bethesda,Maryland - March 15-18, 1998, PROSTATE, 38(4), 1999, pp. 317-360

Authors: Aaltomaa, S Eskelinen, M Lipponen, P
Citation: S. Aaltomaa et al., Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival, PROSTATE, 38(3), 1999, pp. 175-182

Authors: Stege, RH Tribukait, B Carlstrom, KAM Grande, M Pousette, AHL
Citation: Rh. Stege et al., Tissue PSA from fine-needle biopsies of prostatic carcinoma as related to serum PSA, clinical stage, cytological grade, and DNA ploidy, PROSTATE, 38(3), 1999, pp. 183-188

Authors: Eichholzer, M Stahelin, HB Ludin, E Bernasconi, F
Citation: M. Eichholzer et al., Smoking, plasma vitamins C, E, retinol, and carotene, and fatal prostate cancer: Seventeen-year follow-up of the prospective Basel study, PROSTATE, 38(3), 1999, pp. 189-198

Authors: Chung, TDK Yu, JQJ Spiotto, MT Bartkowski, M Simons, JW
Citation: Tdk. Chung et al., Characterization of the role of IL-6 in the progression of prostate cancer, PROSTATE, 38(3), 1999, pp. 199-207

Authors: Goepel, M Hecker, U Krege, S Rubben, H Michel, MC
Citation: M. Goepel et al., Saw palmetto extracts potently and noncompetitively inhibit human alpha(1)-adrenoceptors in vitro, PROSTATE, 38(3), 1999, pp. 208-215

Authors: Smith, P Rhodes, NP Ke, YQ Foster, CS
Citation: P. Smith et al., Influence of the alpha(1)-adrenergic antagonist, doxazosin, on noradrenaline-induced modulation of cytoskeletal proteins in cultured hyperplastic prostatic stromal cells, PROSTATE, 38(3), 1999, pp. 216-227

Authors: Liang, JY Fontana, JA Rao, JN Ordonez, JV Dawson, MI Shroot, B Wilber, JF Feng, P
Citation: Jy. Liang et al., Synthetic retinoid CD437 induces S-phase arrest and apoptosis in human prostate cancer cells LNCaP and PC-3, PROSTATE, 38(3), 1999, pp. 228-236

Authors: Costello, LC Franklin, RB Narayan, P
Citation: Lc. Costello et al., Citrate in the diagnosis of prostate cancer, PROSTATE, 38(3), 1999, pp. 237-245

Citation: Abstracts from the 1998 International Symposium on Biology of Prostate Growth - National Institutes of Health - Natcher Conference Center - Bethesda,Maryland - March 15-18, 1998, PROSTATE, 38(3), 1999, pp. 247-258

Authors: Labrie, F Candas, B Dupont, A Cusan, L Gomez, JL Suburu, RE Diamond, P Levesque, J Belanger, A
Citation: F. Labrie et al., Screening decreases prostate cancer death: First analysis of the 1988 Quebec prospective randomized controlled trial, PROSTATE, 38(2), 1999, pp. 83-91

Authors: Erbersdobler, A Bardenhagen, P Henke, RP
Citation: A. Erbersdobler et al., Numerical chromosomal anomalies in latent adenocarcinomas of the prostate, PROSTATE, 38(2), 1999, pp. 92-99

Authors: Rosendahl, I Kiebert, GM Curran, D Cole, BF Weeks, JC Denis, LJ Hall, RR
Citation: I. Rosendahl et al., Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: Comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer, PROSTATE, 38(2), 1999, pp. 100-109

Authors: Sensibar, JA Pruden, ST Kasjanski, RZ Rademaker, A Lee, C Grayhack, JT Kozlowski, JM
Citation: Ja. Sensibar et al., Differential growth rates in stromal cultures of human prostate derived from patients of varying ages, PROSTATE, 38(2), 1999, pp. 110-117

Authors: Garde, SV Basrur, VS Li, L Finkelman, MA Krishan, A Wellham, L Ben-Josef, E Haddad, M Taylor, JD Porter, AT Tang, DG
Citation: Sv. Garde et al., Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis, PROSTATE, 38(2), 1999, pp. 118-125

Authors: Vacherot, F Caruelle, D Chopin, D Gil-Diez, S Barritault, D Caruelle, JP Courty, J
Citation: F. Vacherot et al., Involvement of heparin affin regulatory peptide in human prostate cancer, PROSTATE, 38(2), 1999, pp. 126-136

Authors: Turk, TMT Rees, MA Pietrow, P Myers, CE Mills, SE Gillenwater, JY
Citation: Tmt. Turk et al., Determination of optimal freezing parameters of human prostate cancer in anude mouse model, PROSTATE, 38(2), 1999, pp. 137-143

Authors: Nixon, RG Meyer, GE Brawer, MK
Citation: Rg. Nixon et al., Differences in prostate size between patients from university and veteransaffairs medical center populations, PROSTATE, 38(2), 1999, pp. 144-150

Authors: Koppan, M Nagy, A Schally, AV Plonowski, A Halmos, G Arencibia, JM Groot, K
Citation: M. Koppan et al., Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice, PROSTATE, 38(2), 1999, pp. 151-158

Authors: Reiter, E Hennuy, B Bruyninx, M Cornet, A Klug, M McNamara, M Closset, J Hennen, G
Citation: E. Reiter et al., Effects of pituitary hormones on the prostate, PROSTATE, 38(2), 1999, pp. 159-165

Authors: Tindall, DJ Scardino, PT
Citation: Dj. Tindall et Pt. Scardino, Defeating prostate cancer: Crucial directions for research-excerpt from the report of the prostate cancer progress review group, PROSTATE, 38(2), 1999, pp. 166-171
Risultati: << | 401-425 | 426-450 | 451-475 | 476-500 | >>